Survey of cannabis use in patients with amyotrophic lateral sclerosis

Cannabis (marijuana) has been proposed as treatment for a widening spectrum of medical conditions and has many properties that may be applicable to the management of amyotrophic lateral sclerosis (ALS). This study is the first, anonymous survey of persons with ALS regarding the use of cannabis. There were 131 respondents, 13 of whom reported using cannabis in the last 12 months. Although the small number of people with ALS that reported using cannabis limits the interpretation of the survey findings, the results indicate that cannabis may be moderately effective at reducing symptoms of appetite loss, depression, pain, spasticity, and drooling. Cannabis was reported ineffective in reducing difficulties with speech and swallowing, and sexual dysfunction. The longest relief was reported for depression (approximately two to three hours).

[1]  A. Alpérovitch,et al.  Rising amyotrophic lateral sclerosis mortality in France 1968–1990: Increased life expectancy and inter-disease competition as an explanation , 1994, Journal of Neurology.

[2]  B. Conrad,et al.  Effect of cannabinoids on spasticity and ataxia in multiple sclerosis , 1989, Journal of Neurology.

[3]  J. Mendelson,et al.  Effects of marihuana use on body weight and caloric intake in humans , 1976, Psychopharmacology.

[4]  L. Hollister,et al.  Terminal elimination plasma half-life of Δ1-tetrahydrocannabinol (Δ1-THC) in heavy users of marijuana , 2004, European Journal of Clinical Pharmacology.

[5]  T. Möller,et al.  Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. , 2002, Current opinion in investigational drugs.

[6]  G. Carter,et al.  Cannabis: old medicine with new promise for neurological disorders. , 2002, Current opinion in investigational drugs.

[7]  G. Borasio,et al.  The use of alternative medicine by patients with amyotrophic lateral sclerosis , 2001, Journal of the Neurological Sciences.

[8]  G. Carter,et al.  Marijuana in the management of amyotrophic lateral sclerosis , 2001, The American journal of hospice & palliative care.

[9]  M. Cudkowicz,et al.  The ALS Patient Care Database: Insights into End-of-Life Care in ALS , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[10]  J. Buck,et al.  Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  R. Rosenthal,et al.  Neuroprotective Antioxidants from Marijuana a , 2000, Annals of the New York Academy of Sciences.

[12]  J. D. Richardson,et al.  Cannabinoids modulate pain by multiple mechanisms of action , 2000 .

[13]  R. Abresch,et al.  Expanding the role of hospice care in amyotrophic lateral sclerosis , 1999, The American journal of hospice & palliative care.

[14]  S. Edworthy.  World Wide Web: Opportunities, challenges, and threats , 1999, Lupus.

[15]  K. Jin,et al.  Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures , 1999, The Journal of Neuroscience.

[16]  H. Fields,et al.  An analgesia circuit activated by cannabinoids , 1998, Nature.

[17]  J. Axelrod,et al.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. J. Gurley,et al.  Medicinal marijuana: a comprehensive review. , 1998, Journal of psychoactive drugs.

[19]  R. Miller,et al.  Comprehensive management of amyotrophic lateral sclerosis. , 1998, Physical medicine and rehabilitation clinics of North America.

[20]  A. Gharavi,et al.  Hypercoagulable States , 1997, Annals of Internal Medicine.

[21]  R. Schwartz,et al.  Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana , 1997, Annals of Internal Medicine.

[22]  J. Rein,et al.  The perceived effects of smoked cannabis on patients with multiple sclerosis. , 1997, European neurology.

[23]  B. Martin,et al.  Cannabis: pharmacology and toxicology in animals and humans. , 1996, Addiction.

[24]  S. Mascarella,et al.  Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. , 1996, Journal of medicinal chemistry.

[25]  D. Yurgelun-Todd,et al.  The residual cognitive effects of heavy marijuana use in college students. , 1996, JAMA.

[26]  K. Shepard,et al.  Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. , 1995, Journal of pain and symptom management.

[27]  A. Eisen.  Amyotrophic lateral sclerosis is a multifactorial disease. , 1995, Muscle & nerve.

[28]  S. Neilson,et al.  Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966–1989: evidence for a susceptible subpopulation , 1994, Journal of the Neurological Sciences.

[29]  D. Walsh,et al.  A Phase II Study of Delta-9-Tetrahydrocannabinol for Appetite Stimulation in Cancer-Associated Anorexia , 1994, Journal of palliative care.

[30]  S. Werness,et al.  Short‐term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers , 1994, Clinical pharmacology and therapeutics.

[31]  A. Biegon,et al.  HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. , 1993, Neuroreport.

[32]  F. Norris,et al.  Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.

[33]  J. R. Brinkmann,et al.  The natural history of amyotrophic lateral sclerosis , 1993, Neurology.

[34]  M. Polen,et al.  Health care use by frequent marijuana smokers who do not smoke tobacco. , 1993, The Western journal of medicine.

[35]  A. Eisen,et al.  Duration of amyotrophic lateral sclerosis is age dependent , 1993, Muscle & nerve.

[36]  R. Mechoulam,et al.  A random walk through a cannabis field , 1991, Pharmacology Biochemistry and Behavior.

[37]  Z. Seltzer,et al.  Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties , 1991, Pain.

[38]  D. Perl,et al.  RISING MORTALITY FROM MOTONEURON DISEASE IN THE USA, 1962-84 , 1989, The Lancet.

[39]  L. Hollister,et al.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. , 1989, European journal of clinical pharmacology.

[40]  R. Foltin,et al.  Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory , 1988, Appetite.

[41]  A. Jones.  Reliability of breath-alcohol measurements during the absorption phase. , 1987, Clinical chemistry.

[42]  R. Jones.  Drug of abuse profile: cannabis. , 1987, Clinical chemistry.

[43]  V. Chandra,et al.  Motor neuron disease in the United States, 1971 and 1973–1978 , 1987, Neurology.

[44]  L. Hollister,et al.  Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. , 1986, Pharmacological reviews.

[45]  R. Herning,et al.  Clinical Relevance of Cannabis Tolerance and Dependence , 1981, Journal of clinical pharmacology.

[46]  R. Noyes,et al.  The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine , 1975, Clinical pharmacology and therapeutics.

[47]  R. Noyes,et al.  Analgesic Effect of Delta‐9‐Tetrahydrocannabinol , 1975, Journal of clinical pharmacology.